New antibody drug takes aim at Hard-to-Treat cancers
NCT ID NCT06126666
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 21 times
Summary
This early-phase trial is testing a new drug called ABL103 in people with advanced solid tumors that have stopped responding to standard treatments. The study aims to find the safest dose and check for side effects. About 96 participants will receive the drug to see if it can help control their cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam, Seoul, 13620, South Korea
Contact
Contact Email: •••••@•••••
-
Seoul National University Hospital
NOT_YET_RECRUITINGSeoul, Seoul, 03080, South Korea
Contact Email: •••••@•••••
-
Sevrance Hospital
RECRUITINGSeoul, South Korea, 03722, South Korea
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.